Chromogranin A as a Predictor of Progression, Regression or Stable Disease in Ileo-Cecal Neuroendocrine Tumors

被引：0
|
作者：
Jensen, K. [1 ,2 ]
Hilsted, L. [2 ]
Jensen, C. [2 ]
Mynster, T. [2 ]
Knigge, U. [2 ]
机构：
[1] Slagelse Hosp, Dept Surg, Copenhagen, Denmark
[2] Rigshosp, Neuroendocrine Tumor Ctr Excellence, DK-2100 Copenhagen, Denmark
来源：
NEUROENDOCRINOLOGY | 2011年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [31] Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors
    Núria Buil-Bruna
    Marion Dehez
    Amandine Manon
    Thi Xuan Quyen Nguyen
    Iñaki F. Trocóniz
    The AAPS Journal, 2016, 18 : 703 - 712
  • [32] Well-differentiated neuroendocrine tumors of the appendix: Diagnosis, differentials, and disease progression
    Navale, Pooja
    Gonzalez, Raul S.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2024, 41 (05) : 236 - 242
  • [33] Postoperative outcome in 2890 patients following right hemicolectomy and ileo-cecal resection in colonic cancer and Crohn's disease: results from ESCP-SECCO snapshot prospective audit 2015
    Grandt, S. Dich
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S57 - S57
  • [34] The influence of somatostatin analog on serum Chromogranin A and progression of disease among patients with neuroendocrine carcinoma, carcinoid type: A descriptive study
    Gardner, N
    Foulis, PR
    Fan, Z
    Kvols, L
    BRITISH JOURNAL OF CANCER, 2002, 86 : S116 - S116
  • [35] Association between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
    Delea, T. E.
    Rotter, J.
    Wang, X.
    NEUROENDOCRINOLOGY, 2011, 94 : 22 - 22
  • [36] Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors
    Ronot, Maxime
    Burgio, Marco Dioguardi
    Gregory, Jules
    Hentic, Olivia
    Vullierme, Marie-Pierre
    Ruszniewski, Philippe
    Zappa, Magaly
    de Mestier, Louis
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (05)
  • [37] Value of Re-Biopsy of Liver Metastases of Patients with Neuroendocrine Tumors in Disease Progression
    Emelianova, G.
    Delektorskaya, V
    Gorbunova, V
    Markovich, A.
    Orel, N.
    NEUROENDOCRINOLOGY, 2019, 108 : 105 - 105
  • [38] Heme Oxygenase-1 Promoter Polymorphism is a Predictor of Disease Relapse in Pancreatic Neuroendocrine Tumors
    Vashist, Yogesh K.
    Uzunoglu, Guentac
    Deutsch, Lena
    Kalinin, Viacheslav
    Zehler, Oliver
    Alzadjali, Adil
    Kutup, Asad
    Izbicki, Jakob R.
    Yekebas, Emre F.
    JOURNAL OF SURGICAL RESEARCH, 2011, 166 (02) : E121 - E127
  • [39] Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease
    Espen Thiis-Evensen
    Amalie Christine Poole
    Hong-Thien Thi Nguyen
    Jon Sponheim
    BMC Cancer, 20
  • [40] Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease
    Thiis-Evensen, E.
    Sponheim, J.
    NEUROENDOCRINOLOGY, 2020, 110 : 241 - 241
12345